Siegfried Holding AG

siegfried.ch

Expect more with Siegfried as your preferred partner. Siegfried is a preferred manufacturing and service partner in the global pharmaceutical industry. Our company is looking back on more than 140 years of unmatched quality and combines both chemistry and pharmaceutics under one roof.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharmacy Market

ORBIT DISCOVERY AND WUXI APPTEC SIGN AGREEMENT TO ACCESS PEPTIDE DISCOVERY AND OPTIMISATION TECHNOLOGIES

Orbit Discovery | March 08, 2022

news image

Orbit Discovery a ground-breaking peptide discovery company is pleased to announce the commencement of a partnership with WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry. Orbit will combine its leading peptide discovery platform and experience with WuXi AppTec’s downstream capabilities. Specifically, Orbit gains access to WuXi AppTec’s expertise in peptide optimisation, peptide p...

Read More

Pharma Tech

PORTON ADVANCED AND ROYALTECH ANNOUNCE STRATEGIC COLLABORATION TO ACCELERATE THE DEVELOPMENT OF BACTERIAL DRUGS AND MRNA DRUGS

Porton Advanced Solutions | August 29, 2022

news image

Porton Advanced Solutions.announced a strategic cooperation with Suzhou Royaltech Med Co., Ltd. This strategic collaboration will further integrate the resources and capabilities of both parties, jointly promote the establishment of microbial vectors used for gene therapy and mRNA drug platform technology, and accelerate the R&D process of bioinnovative drugs. Porton Advanced provides an end-to-end gene and cell therapy CDMO service platform covering plasmids, cell therapy, ge...

Read More

Business Insights

ADALVO PARTNERS WITH SK PHARMA TO CREATE ARPHIO, A NEW BUSINESS ENTITY DEDICATED SOLELY TO ORPHAN AND RARE DISEASE MEDICINES

Adalvo | March 01, 2022

news image

Adalvo, the leading global B2B pharmaceutical company, is thrilled to announce the recent establishment of a new entity ArphioTM a venture initiated in close collaboration with SK Pharma. Together with our new partner, we are developing a powerhouse, solely dedicated to orphan drugs with the intention of improving accessibility of vital treatments, to patients suffering from rare diseases and unmet medical needs. ArphioTM will operate as an independent entity, focus...

Read More

Business Insights, PHARMACY MARKET

TETRIS PHARMA SIGNS SERVICE AGREEMENT WITH SYNEOS HEALTH

Tetris Pharma Ltd | December 13, 2022

news image

Tetris Pharma Ltd a subsidiary of biopharmaceutical company, Arecor Therapeutics plc announces that it has signed a service agreement with Syneos Health® the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success, to support the build out of Tetris Pharma’s commercial platform across Europe. Through this partnership, Syneos Health will provide commercial support through an outsourced contract sales services to accelera...

Read More
news image

Pharmacy Market

ORBIT DISCOVERY AND WUXI APPTEC SIGN AGREEMENT TO ACCESS PEPTIDE DISCOVERY AND OPTIMISATION TECHNOLOGIES

Orbit Discovery | March 08, 2022

Orbit Discovery a ground-breaking peptide discovery company is pleased to announce the commencement of a partnership with WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry. Orbit will combine its leading peptide discovery platform and experience with WuXi AppTec’s downstream capabilities. Specifically, Orbit gains access to WuXi AppTec’s expertise in peptide optimisation, peptide p...

Read More
news image

Pharma Tech

PORTON ADVANCED AND ROYALTECH ANNOUNCE STRATEGIC COLLABORATION TO ACCELERATE THE DEVELOPMENT OF BACTERIAL DRUGS AND MRNA DRUGS

Porton Advanced Solutions | August 29, 2022

Porton Advanced Solutions.announced a strategic cooperation with Suzhou Royaltech Med Co., Ltd. This strategic collaboration will further integrate the resources and capabilities of both parties, jointly promote the establishment of microbial vectors used for gene therapy and mRNA drug platform technology, and accelerate the R&D process of bioinnovative drugs. Porton Advanced provides an end-to-end gene and cell therapy CDMO service platform covering plasmids, cell therapy, ge...

Read More
news image

Business Insights

ADALVO PARTNERS WITH SK PHARMA TO CREATE ARPHIO, A NEW BUSINESS ENTITY DEDICATED SOLELY TO ORPHAN AND RARE DISEASE MEDICINES

Adalvo | March 01, 2022

Adalvo, the leading global B2B pharmaceutical company, is thrilled to announce the recent establishment of a new entity ArphioTM a venture initiated in close collaboration with SK Pharma. Together with our new partner, we are developing a powerhouse, solely dedicated to orphan drugs with the intention of improving accessibility of vital treatments, to patients suffering from rare diseases and unmet medical needs. ArphioTM will operate as an independent entity, focus...

Read More
news image

Business Insights, PHARMACY MARKET

TETRIS PHARMA SIGNS SERVICE AGREEMENT WITH SYNEOS HEALTH

Tetris Pharma Ltd | December 13, 2022

Tetris Pharma Ltd a subsidiary of biopharmaceutical company, Arecor Therapeutics plc announces that it has signed a service agreement with Syneos Health® the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success, to support the build out of Tetris Pharma’s commercial platform across Europe. Through this partnership, Syneos Health will provide commercial support through an outsourced contract sales services to accelera...

Read More

Resources

resource image

Research, Business Insights

Navigating a Stringent Regulatory Landscape

Video

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us